Exact Sciences Completes Acquisition of Ashion Analytics, LLC, from The Translational Genomics Research Institute, an affiliate of City of Hope
Talented team and industry-leading lab will help strengthen the company s sequencing and pipeline capabilities, while broadening its therapy selection and treatment guidance offerings
News provided by
Share this article
(PRNewsfoto/EXACT SCIENCES CORP)
(PRNewsfoto/EXACT SCIENCES CORP)
MADISON, Wis., April 14, 2021 /PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced acquisition of Ashion Analytics, LLC. As a leader in cancer testing, we re committed to providing earlier answers and life-changing treatment guidance to support patients along every step of their cancer journey, said Kevin Conroy, chairman and CEO of Exact Sciences. With Ashion, we ve added a talented team, a CLIA-certified and CAP-accredited lab, deep sequencing capabilities, and one of the most comprehensiv
NCCN Announces Projects to Study Oral Decitabine and Cedazuridine in Collaboration with Taiho Oncology
NCCN Oncology Research Program to oversee projects exploring oral medication combination targeting tumor suppression genes.
News provided by
Share this article
®) Oncology Research Program (ORP) today announced that three projects have been selected to study oral decitabine (35 mg) and cedazuridine (100 mg). The NCCN ORP convened a Scientific Review Committee to review, evaluate, and select awardees and will provide oversight for the two-year studies which will commence later in 2021. Research funding will be provided by a grant from Taiho Oncology, who will also supply the decitabine and cedazuridine tablet.
Share this article
PLYMOUTH MEETING, Pa., April 13, 2021 /PRNewswire/ The April 2021 issue of
JNCCN Journal of the National Comprehensive Cancer Network publishes new research from Memorial Sloan Kettering Cancer Center (MSK) and Gustave Roussy Institute, which suggests that baseline brain imaging should be considered in most patients with metastatic kidney cancer. The researchers studied 1,689 patients with metastatic renal cell carcinoma (mRCC) who had been considered for clinical trial participation at either of the two institutions between 2001 and 2019 and had undergone brain imaging in this context, without clinical suspicion for brain involvement. The researchers discovered 4% had asymptomatic brain metastases in this setting. This group was found to have a low median 1-year overall survival rate (48%), and median overall survival (10.3 months).
JNCCN Study: Important potential role for routine brain imaging in advanced kidney cancer eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
of
LEXINGTON, Ky. (April 12, 2021) With COVID-19 vaccinations continuing to roll out across the country, the University of Kentucky Markey Cancer Center strongly encourages both cancer survivors, caregivers and patients in active cancer treatment to receive one of the available vaccines. This is in line with recommendations from both the Centers for Disease Control and Prevention (CDC) and the American Cancer Society.
As of Monday, April 5, any Kentuckian age 16 and up is eligible to get the Pfizer vaccine. The Moderna and Johnson & Johnson vaccines are available to anyone age 18 and older. Given the higher rates of severe COVID-19 infection in cancer patients, the American Society of Clinical Oncology and the CDC recommend that cancer patients strongly consider vaccination against COVID-19, said Dr. Frederick R. Ueland, gynecologic oncologist and director of oncology clinical operations at the UK Markey Cancer Center. This includes cancer survivors, most patients undergo